Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carryn M Anderson

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Redox Biology|January 12, 2024
The antioxidant and anti-inflammatory activities of avasopasem manganese in age-associated, cisplatin-induced renal injuryKranti A Mapuskar, Casey F Pulliam, Ann Tomanek-Chalkley, et al.
International Journal of Radiation Oncology, Biology, Physics|November 28, 2017
Phase 1b/2a Trial of the Superoxide Dismutase Mimetic GC4419 to Reduce Chemoradiotherapy-Induced Oral Mucositis in Patients With Oral Cavity or Oropharyngeal CarcinomaCarryn M Anderson, Stephen T Sonis, Christopher M Lee, et al.
Radiation Research|June 4, 2021
Ketogenic Diet with Concurrent Chemoradiation in Head and Neck Squamous Cell Carcinoma: Preclinical and Phase 1 Trial ResultsDaniel C Ma, Carryn M Anderson, Samuel N Rodman, et al.
Cancer|March 11, 2026
Patient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinomaLisa A Kachnic, Jennifer Moughan, Theodore S Hong, et al.
The Lancet. Oncology|January 17, 2022
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trialHoward P Safran, Kathryn Winter, David H Ilson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2019
Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck CancerCarryn M Anderson, Christopher M Lee, Deborah P Saunders, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Redox Biology|January 12, 2024
The antioxidant and anti-inflammatory activities of avasopasem manganese in age-associated, cisplatin-induced renal injuryKranti A Mapuskar, Casey F Pulliam, Ann Tomanek-Chalkley, et al.
International Journal of Radiation Oncology, Biology, Physics|November 28, 2017
Phase 1b/2a Trial of the Superoxide Dismutase Mimetic GC4419 to Reduce Chemoradiotherapy-Induced Oral Mucositis in Patients With Oral Cavity or Oropharyngeal CarcinomaCarryn M Anderson, Stephen T Sonis, Christopher M Lee, et al.
Radiation Research|June 4, 2021
Ketogenic Diet with Concurrent Chemoradiation in Head and Neck Squamous Cell Carcinoma: Preclinical and Phase 1 Trial ResultsDaniel C Ma, Carryn M Anderson, Samuel N Rodman, et al.
Cancer|March 11, 2026
Patient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinomaLisa A Kachnic, Jennifer Moughan, Theodore S Hong, et al.
The Lancet. Oncology|January 17, 2022
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trialHoward P Safran, Kathryn Winter, David H Ilson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2019
Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck CancerCarryn M Anderson, Christopher M Lee, Deborah P Saunders, et al.
Pageof 4